ReviewThe Lancet regional health. Southeast Asia2023
The National List of Essential Medicines of India 2022 (NLEM 2022): Tommy, Toe the Line.
Review in The Lancet regional health. Southeast Asia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Digital platform for prescription analytics and antibiotic surveillance in an outpatient department setup.Indian journal of pharmacology · 2025Observational
- Assessment of antibiotic utilization patterns in an Indian Level-1 Trauma Center: a pilot study exploring days of antibiotic spectrum coverage and defined daily doses using WHO AWaRe classification trends.Frontiers in antibiotics · 2025Article
- Cardiovascular Diseases Among Indian Older Adults: A Comprehensive Review.Cardiovascular therapeutics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
India recently released its fifth National List of Essential Medicines 2022 (NLEM 2022). A critical analysis of the list was performed and was compared with the WHO 22nd Model List of Essential Medicines published in 2021. The Standing National Committee, since its inception, have taken four years to finalise a list. The analysis identified that all the available formulations and strengths of the selected drugs are included in the list, which must be avoided. Furthermore, the antibacterial agents are not categorised as access, watch and reserve (AWaRe) and this list is not aligned with the national programs, standard treatment guidelines and nomenclature. There are a few factual errors and some typographic errors. These problems in the list need to be rectified immediately so that the document would be able to serve the community more effectively as a true model list.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.